SHATTUCK LABS INC (STTK) Stock News
NASDAQ:STTK - Nasdaq - US82024L1035 - Common Stock - Currency: USD
STTK Latest News, Press Relases and Analysis
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shattuck Labs (NASDAQ:STTK) just reported results for the second quarter of 202...
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
Shattuck Labs Announces Participation in Upcoming December Conferences
AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the...
Shattuck Labs Announces Participation in Upcoming December Conferences
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash...
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK). Such...
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc....
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic...
STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024
STTK stock results show that Shattuck Labs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company...
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution. Shattuck’s addition will be effective today when the U.S. equity markets open.